$CMPX News

Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)

How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing

Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics to Participate in Upcoming June Investor Events

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile

Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Q1 EPS $(0.10), Inline

Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?

Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7

Compass Therapeutics’s stock crashes after OS miss in BTC trial

Citizens Reiterates Market Outperform on Compass Therapeutics, Maintains $10 Price Target

Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS Data

This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design.

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript

HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $24 Price Target

Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients